UNASSIGNED: A comprehensive literature search was undertaken across various databases (PubMed/MEDLINE, Embase, Scopus), with no language restriction, for relevant articles (case series, reviews, case reports) pertaining to EUS-RFA for insulinoma and PNETs, till October 2023. In this review, we have explicated the role of EUS-RFA for insulinoma management, detailing thoroughly its mechanism of action, EUS-RFA devices with data on its safety and efficacy, and an algorithmic approach for its management.
UNASSIGNED: EUS-RFA is being advocated as a \'mini-invasive\' option with the potential to replace surgery as a first-line approach for benign, sporadic, solitary, and small (<2 cm) insulinomas. Under real-time guidance, EUS-RFA has immense precision, is safe, predictable, with acceptable safety profile. Presently, it is being frequently performed for high-risk or inoperable candidates. Current need-of-the-hour is a randomized controlled trial to substantiate its role in the therapeutic algorithm for insulinoma management.
■在各种数据库中进行了全面的文献检索(PubMed/Medline,Embase,Scopus),没有语言限制,对于相关文章(案例系列,reviews,病例报告)与胰岛素瘤和PNETs的EUS-RFA有关,直到2023年10月。在这次审查中,我们已经阐明了EUS-RFA在胰岛素瘤治疗中的作用,彻底详述其作用机制,EUS-RFA设备及其安全性和有效性数据,以及其管理的算法方法。
■EUS-RFA被提倡为“微型侵入性”选项,有可能取代手术作为良性疾病的一线治疗方法,零星的,孤独,和小(<2厘米)胰岛素瘤。在实时指导下,EUS-RFA具有极高的精度,是安全的,可预测的,具有可接受的安全性。目前,它经常被用于高风险或无法操作的候选人。当前的小时需求是一项随机对照试验,以证实其在胰岛素瘤治疗算法中的作用。